The use of embryonic stem cells for regulatory developmental toxicity testing in vitro -: The current status of test development

被引:63
作者
Bremer, S [1 ]
Hartung, T [1 ]
机构
[1] Commiss European Communities, Inst Hlth & Consumer Protect, Joint Res Ctr, ECVAM, I-21020 Ispra, VA, Italy
关键词
embryonic stem cells; developmental toxicity; alternative method; chemical policy; test strategy;
D O I
10.2174/1381612043383700
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The future chemical policy of the European Union as well as the 7th amendment of the cosmetic directive is calling for the development of alternative tests to animal experimentation for toxicological safety testing. In the field of embryotoxicity one or the most promising in vitro models are based on embryonic stein cells. The embryonic stem cell test has already been validated in comparison to in vivo results in an international blind collaboration study. The presented review is discussing the use, limitations and further needs for the test in order to be fully suitable for regulatory acceptance. In this context, it is summarized which requirements for an in vitro embryotoxicity test have to be fulfilled for regulatory toxicity testing. In addition, an overview about the Current status of test development of other embryonic stem cell tests is presented. Several workshops have reviewed the progress of in vitro tests for developmental toxicity testing. A general consensus Of these workshops has been that one single test will not be sufficient to cover all manifestations of developmental toxicity. The establishment of a test battery for developmental toxicity is required. This will be even more challenging since the principles of a composing test strategy and its validation have not been defined yet. Finally, the unique possibility of combining the human embryonic stem cell technology and the microarray techniques might lead to a deeper understanding of the toxicological mechanisms of human developmental toxicants.
引用
收藏
页码:2733 / 2747
页数:15
相关论文
共 106 条
  • [71] PRATT RM, 1982, TERATOGEN CARCIN MUT, V2, P313, DOI 10.1002/1520-6866(1990)2:3/4<313::AID-TCM1770020312>3.0.CO
  • [72] 2-C
  • [73] Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: present state and future prospects
    Rohwedel, J
    Guan, K
    Hegert, C
    Wobus, AM
    [J]. TOXICOLOGY IN VITRO, 2001, 15 (06) : 741 - 753
  • [74] Formation of postsynaptic-like membranes during differentiation of embryonic stem cells in vitro
    Rohwedel, J
    Kleppisch, T
    Pich, U
    Guan, K
    Jin, S
    Zuschratter, W
    Hopf, C
    Hoch, W
    Hescheler, J
    Witzemann, V
    Wobus, AM
    [J]. EXPERIMENTAL CELL RESEARCH, 1998, 239 (02) : 214 - 225
  • [75] ACTIN AND MYOSIN EXPRESSION DURING DEVELOPMENT OF CARDIAC-MUSCLE FROM CULTURED EMBRYONAL CARCINOMA-CELLS
    RUDNICKI, MA
    JACKOWSKI, G
    SAGGIN, L
    MCBURNEY, MW
    [J]. DEVELOPMENTAL BIOLOGY, 1990, 138 (02) : 348 - 358
  • [76] SADLER TW, 1982, TERATOGEN CARCIN MUT, V2, P243, DOI 10.1002/1520-6866(1990)2:3/4<243::AID-TCM1770020306>3.0.CO
  • [77] 2-U
  • [78] Scholz G, 1998, ALTEX-ALTERN TIEREXP, V15, P3
  • [79] Embryotoxicity screening using embryonic stem cells in vitro: Correlation to in vivo teratogenicity
    Scholz, G
    Pohl, I
    Genschow, E
    Klemm, M
    Spielmann, H
    [J]. CELLS TISSUES ORGANS, 1999, 165 (3-4) : 203 - 211
  • [80] Distant upstream regulatory domains direct high levels of β-myosin heavy chain gene expression in differentiated embryonic stem cells
    Schreiber, KL
    Calderone, A
    Rindt, H
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (04) : 585 - 598